Introduction {#s1}
============

Acute myeloid leukemia (AML), a cancer of the myeloid line of blood cells, is the most common acute leukemia affecting adult [@pone.0055473-Jiang1]. The abnormal white blood cells accumulate in the bone marrow, thus interfering with the production of normal blood cells. Although most cases of AML have no obvious cause, it is considered that several factors may play a role in the increased occurrence of AML, including chemical exposure [@pone.0055473-LeBeau1], [@pone.0055473-Thirman1], ionizing radiation [@pone.0055473-Gunz1], and genetics [@pone.0055473-Evans1].

Interleukin (IL)-23 is a heterodimeric proinflammatory cytokine composed of a p19 subunit and a p40 subunit, which is also part of IL-12 [@pone.0055473-DelVecchio1], [@pone.0055473-Trinchieri1]. IL-23 is predominantly produced by antigen-presenting cells in response to microbial or host immune stimuli and is involved in the regulation of immune responses against infections and tumor development through the engagement of the IL-23 receptor (IL-23R) [@pone.0055473-Hunter1]. Recent studies also showed the direct antitumor activities of IL-23/IL-23R in human hematologic malignancies, i.e., pediatric acute leukemia, and IL-23 directly dampens tumor growth in vitro and in vivo through the inhibition of tumor cell proliferation and induction of apoptosis [@pone.0055473-Cocco1], [@pone.0055473-Cocco2]. The *IL-23R* gene located on chromosome 1p31 encodes one subunit of the IL-23R [@pone.0055473-Parham1].Two potentially functional common variants of *IL-23R*, rs6682925 (T\>C) located at 907-bp upstream from the transcriptional start position, and rs1884444 (T\>G) located at codon 3 with amino acid His substituted by Gln in exon 2, have been shown to have association with risk of several solid cancers [@pone.0055473-Xu1]--[@pone.0055473-Chen1]. Here, we hypothesized these two single-nucleotide polymorphisms (SNPs) may also be associated with risk of AML.

Results {#s2}
=======

Of the 545 AML cases, 291 (53.4%) were males and the mean age at diagnosis was 44.1±17.2 years old, while among the 1146 cancer-free controls, 820 (71.5%) were males and the mean age was 59.0±9.7 years old. The clinical and cytogenetic characteristics of the AML cases are summarized in [Table 1](#pone-0055473-t001){ref-type="table"}.

10.1371/journal.pone.0055473.t001

###### Clinical Characteristics of AML Patients.
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  Characteristics                     AML (n = 545)  
  ---------------------------------- --------------- ------
  **Lineage**                                        
  Myeloid                                  378        69.4
  Myeloid and Lymphoid                     157        28.8
  Myeloid and Monocytic                    10         1.8
  **Classification of diagnosis**                    
  M0                                        3         0.6
  M1                                       103        18.9
  M2                                       175        32.1
  M3                                       90         16.5
  M4                                       58         10.6
  M5                                       89         16.3
  Unknown                                  27         5.0
  **Karyotype**                                      
  Aberrant                                 246        45.1
  t(9;22)                                  11         2.0
  t(8;21)                                  48         8.8
  t(15;17)                                 64         11.7
  complex                                  114        20.9
  others                                    9         1.7
  Normal                                   235        43.1
  Unknown                                  64         11.8
  **Molecular subtype**                              
  Common fusion gene transcripts           187        34.3
  PML/RARα                                 77         14.1
  BCR/ABL                                  13         2.4
  AML1/ETO                                 54         9.9
  CBFβ/MYH11                               10         1.8
  MLL rearrangement                        15         2.8
  WT1                                      11         2.0
  Others                                    7         1.3
  No common fusion gene ranscripts         303        55.6
  Unknown                                  55         10.1

Genotyping was successfully performed in 537 cases and 1137 controls for rs1884444 (call rate = 99.0%) and 525 cases and 1117 controls for rs6682925 (call rate = 97.1%). The genotype distributions of these two variants between the cases and controls are shown in [Table 2](#pone-0055473-t002){ref-type="table"}. The observed genotype frequencies for both variants were in Hardy-Weinberg equilibrium among the controls (*P* = 0.829 for rs1884444 and *P* = 0.686 for rs6682925). Multivariate logistic regression analysis showed that the rs1884444 TG and combined genotypes TG/GG were associated with a significantly increased risk of AML (adjusted OR = 1.34, 95%CI = 1.04--1.72 for TG; adjusted OR = 1.28, 95% CI = 1.01--1.62 for TG/GG), compared with the rs1884444 wild-type TT, respectively. Similarly, compared to the wild TT genotype, rs6682925 CC and combined TC/CC genotypes contributed to AML risk by 1.48-fold (95% CI = 1.03--2.13) and 1.30-fold (95% CI = 1.01--1.67), respectively.

10.1371/journal.pone.0055473.t002

###### Distribution of Alleles and Genotypes of *IL-23R* Variants and Their Association with AML Risk.
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                                                         AML (n = 545)   Controls (n = 1146)   OR (95%CI)[a](#nt101){ref-type="table-fn"}   *P* [a](#nt101){ref-type="table-fn"}   OR (95%CI)[b](#nt102){ref-type="table-fn"}   *P* [b](#nt102){ref-type="table-fn"}                     
  ----------------------------------------------------- --------------- --------------------- -------------------------------------------- -------------------------------------- -------------------------------------------- -------------------------------------- ------------------ -------
  **rs1884444 T\>G** [c](#nt103){ref-type="table-fn"}                                                                                                                                                                                                                                    
  TT                                                          223               41.5                              519                                       45.7                                      1.00                                                                   1.00        
  TG                                                          254               47.3                              496                                       43.6                                1.19(0.96, 1.48)                               0.115                   1.34(1.04, 1.72)   0.024
  GG                                                          60                11.2                              122                                       10.7                                1.15(0.81, 1.62)                               0.445                   1.05(0.70, 1.57)   0.814
  TG/GG                                                       314               58.5                              618                                       54.3                                1.18(0.96, 1.46)                               0.113                   1.28(1.01, 1.62)   0.047
  G allele                                                   34.8%              32.5%                       1.11(0.95, 1.29)                               0.189                                1.12(0.94, 1.34)                               0.214                                     
  **rs6682925 T\>C** [d](#nt104){ref-type="table-fn"}                                                                                                                                                                                                                                    
  TT                                                          184               35.0                              452                                       40.5                                      1.00                                                                   1.00        
  TC                                                          247               47.1                              522                                       46.7                                1.16(0.93, 1.46)                               0.197                   1.25(0.96, 1.62)   0.103
  CC                                                          94                17.9                              143                                       12.8                                1.62(1.18, 2.21)                               0.003                   1.48(1.03, 2.13)   0.033
  TC/CC                                                       341               65.0                              665                                       59.5                                1.26(1.02, 1.56)                               0.036                   1.30(1.01, 1.67)   0.039
  C allele                                                   41.4%              36.2%                       1.25(1.07, 1.45)                               0.004                                1.22(1.03, 1.45)                               0.022                                     

Crude odds ratio (OR), 95% confidence interval (CI) and corresponding *P* value.

Adjusted for age and gender.

Genotypes were unavailable in 8 cases and 9 controls.

Genotypes were unavailable in 20 cases and 29 controls.

Stratified analyses of these two SNPs are summarized in [Table 3](#pone-0055473-t003){ref-type="table"}. No significant heterogeneity between the subgroups was detected for rs6682925. For rs1884444, the increased risk of combined TG/GG genotypes was more significant in older patients (more than 45 years old at diagnosis), and *P* value for the heterogeneity was 0.030. However, there was no interaction between rs1884444 and age on AML risk (*P* = 0.097).

10.1371/journal.pone.0055473.t003

###### Stratification Analysis of rs1884444 and rs6682925 Genotypes by Selected Variables in AML Patients and Controls.
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  Characteristics                     rs1884444   rs6682925                                                                                                                                                     
  ---------------------------------- ----------- ----------- ----- ----- --------------------------------------------------- ------- ----- ----- ----- ----- -------------------------------------------------- -------
  **gender**                                                                                                                                                                                                    
  Male                                   115         172      365   448   1.30(0.95, 1.78)[a](#nt105){ref-type="table-fn"}    0.848   98    183   318   483   1.26(0.91, 1.74)[a](#nt105){ref-type="table-fn"}   0.745
  Female                                 108         142      154   170   1.24(0.86, 1.80)[a](#nt105){ref-type="table-fn"}            86    158   134   182   1.37(0.93, 2.01)[a](#nt105){ref-type="table-fn"}  
  **Age at diagnosis, year**                                                                                                                                                                                    
  ≤45                                    134         159      48    67    0.85(0.55, 1.32)[b](#nt106){ref-type="table-fn"}    0.030   109   179   41    74    0.91(0.58, 1.43)[b](#nt106){ref-type="table-fn"}   0.062
  \>45                                   89          155      471   551   1.52(1.14, 2.04) [b](#nt106){ref-type="table-fn"}           75    162   411   591   1.53(1.13, 2.08)[b](#nt106){ref-type="table-fn"}  
  **Lineage**                                                                                                                                                                                                   
  Myeloid                                158         215      519   618   1.21(0.93, 1.59)[c](#nt107){ref-type="table-fn"}    0.985   131   234   452   665   1.25(0.94, 1.65)[c](#nt107){ref-type="table-fn"}   0.890
  Myeloid and Lymphoid                   61          93       519   618   1.26(0.86, 1.83) [c](#nt107){ref-type="table-fn"}           49    101   452   665   1.32(0.89, 1.95)[c](#nt107){ref-type="table-fn"}  
  Myeloid and Monocytic                   4           6       519   618   1.20(0.34, 4.30) [c](#nt107){ref-type="table-fn"}            4     6    452   665   0.96(0.27, 3.44)[c](#nt107){ref-type="table-fn"}  
  **Karyotype**                                                                                                                                                                                                 
  t(8;21)                                22          26       519   618   0.94(0.51, 1.73) [c](#nt107){ref-type="table-fn"}   0.726   15    31    452   665   1.29(0.67, 2.48)[c](#nt107){ref-type="table-fn"}   0.740
  t(15;17)                               23          39       519   618   1.34(0.74, 2.42) [c](#nt107){ref-type="table-fn"}           21    42    452   665   1.26(0.69, 2.29)[c](#nt107){ref-type="table-fn"}  
  Complex                                53          60       519   618   0.93(0.61, 1.40) [c](#nt107){ref-type="table-fn"}           44    63    452   665   0.91(0.59, 1.39)[c](#nt107){ref-type="table-fn"}  
  Others                                  8          11       519   618   1.05(0.41, 2.69) [c](#nt107){ref-type="table-fn"}            6    13    452   665   1.34(0.50, 3.63)[c](#nt107){ref-type="table-fn"}  
  Normal                                 95          136      519   618   1.27(0.92, 1.74) [c](#nt107){ref-type="table-fn"}           78    148   452   665   1.31(0.94, 1.82)[c](#nt107){ref-type="table-fn"}  
  Unknown                                22          42                                                                               20    44                                       --                         
  **Molecular subtype**                                                                                                                                                                                         
  PML/RARα                               26          50       519   618   1.55(0.90, 2.69) [c](#nt107){ref-type="table-fn"}   0.647   23    51    452   665   1.37(0.78, 2.43)[c](#nt107){ref-type="table-fn"}   0.922
  AML1/ETO                               25          29       519   618   0.94(0.53, 1.66) [c](#nt107){ref-type="table-fn"}           19    33    452   665   1.10(0.60, 2.01)[c](#nt107){ref-type="table-fn"}  
  Others                                 24          32       519   618   1.08(0.61, 1.91) [c](#nt107){ref-type="table-fn"}           21    34    452   665   1.06(0.59, 1.90)[c](#nt107){ref-type="table-fn"}  
  No common fusion gene ranscripts       126         170      519   618   1.17(0.88, 1.56) [c](#nt107){ref-type="table-fn"}           102   188   452   665   1.23(0.92, 1.66)[c](#nt107){ref-type="table-fn"}  
  Unknown                                22          33                                                                               19    35                                                                  

Adjusted for age.

Adjusted for gender.

Adjusted for age and gender.

*P* value for heterogeneity test based on χ^2^-based Q test.

As the fusion gene AML1/ETO and PML/RARαrespectively accounted for the majority of molecular subtypes of M2 AML and M3 AML, we then investigated the association of these two genes and SNPs of *IL-23R* in M2 AML and M3 AML. However, there was no significant associations between AML1/ETO or PML/RARα and *IL-23R* variants in M2 and M3 AML, respectively, as shown in [Table 4](#pone-0055473-t004){ref-type="table"}.

10.1371/journal.pone.0055473.t004

###### Association of AML1/ETO and *IL-23R* Variants in M2 AML, and Association of PML/RARα and *IL-23R* Variants in M3 AML.
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  Classification           Molecularsubtype          rs1884444   rs6682925                                                                                  
  ---------------- -------------------------------- ----------- ----------- ----- ----- ------------------ ------- ---- ---- ----- ----- ------------------ -------
  M2                           AML1/ETO                 20          25       519   618   1.04(0.59, 1.83)   0.709   14   29   452   665   1.21(0.67, 2.20)   0.929
                    No commonfusion generanscripts      51          55       519   618   0.91(0.60, 1.37)           35   66   452   665   1.17(0.76, 1.81)  
                           Unknown & Others              8          14       519   618          --                  7    14   452   665          --         
  M3                           PML/RARα                 26          49       519   618   1.51(0.87, 2.62)   0.241   23   50   452   665   1.33(0.75, 2.37)   0.511
                    No commonfusion generanscripts       5           4       519   618   0.64(0.17, 2.41)           4    5    452   665   0.82(0.22, 3.10)  
                           Unknown & Others              3           1       519   618          --                  3    1    452   665          --         

Adjusted for age and gender;

*P* value for heterogeneity test based on χ^2^-based Q test.

Discussion {#s3}
==========

IL-23 is a proinflammatory heterodimeric cytokine sharing common subunits with IL-12 [@pone.0055473-DelVecchio1], [@pone.0055473-Trinchieri1], which could directly inhibit human acute myeloid leukemia cell growth [@pone.0055473-Ferretti1]. With the similar structures and biological activities of IL-12, IL-23 may also have some effects on human malignancies, whereas its antitumor activity remains controversial. Some groups held the opinion that IL-23 can impair CD8^+^ T-lymphocyte-mediated immune surveillance and promote *de novo* carcinogenesis and tumor neovascularization [@pone.0055473-Langowski1]--[@pone.0055473-Tartour1]. In contrast, other groups have shown that IL-23 exerts antitumor activity through stimulation of T cells and NK cells [@pone.0055473-Oniki1]--[@pone.0055473-Overwijk1]. IL-23 mediates these cancer-related effects through IL-23R. Cocco et al. demonstrated that IL-23/IL-23R acts as antitumor agent on hematologic malignancies including childhood acute leukemia [@pone.0055473-Cocco1], [@pone.0055473-Cocco2]. Recently, several studies evaluated the association between two variants (rs1884444 and rs6682925) of *IL-23R* polymorphisms and risk of solid cancers in Chinese population [@pone.0055473-Xu1]--[@pone.0055473-Chen1]. Xu et al. [@pone.0055473-Xu1] reported that the variant alleles of rs6682925 and rs1884444 both increased the hepatocellular carcinoma risk. Chu et al. [@pone.0055473-Chu1] found that rs6682925 TC/CC and rs1884444 TG/GG variant genotypes were associated with significantly increased risk of esophageal cancer. But Chen et al. [@pone.0055473-Chen1] found the protective effect of rs1884444 G allele in gastric cancer. In this study, we found that the variant alleles of rs1884444 (T\>G) and rs6682925 (T\>C) were associated with an increased risk of AML in a Chinese population, although this type-specific association needs to be confirmed in other studies. However, up to date, only 3 studies focused on the association of rs1884444 with human diseases in non-Chinese population [@pone.0055473-Kim1]--[@pone.0055473-Safrany1], and none of them were involved in leukemia. Additionally, there haven't been any studies focused on rs6682925 in other population except Chinese. So we could not evaluate the presence of these SNPs in non-Chinese population.

Thus far, it is challenging to know the exact mechanisms of these two variants on AML carcinogenesis. The SNP rs1884444 locates at exon 2 of *IL-23R*, which is responsible for the signal peptide of IL-23R [@pone.0055473-Kan1]. According to the wed-based prediction tool of PupaSuite2 (<http://pupasuite.bioinfo.cipf.es/>) [@pone.0055473-Conde1], the T-to-G base change of rs1884444 may disrupt an exonic splicing enhancer, resulting in exon skipping, malformation, or transcript alternative splicing. Another possible explanation is that rs1884444 resulted in amino acid change (His\>Gln), which may influence the ligand-receptor binding specificity and affinity, and thus modulate the proinflammatory effect by Th17 cell and get involved in the development of AML [@pone.0055473-Chen1]. The SNP rs6682925 locates at 907-bp upstream from the transcriptional start position of *IL-23R.* The web-based tool of TFSEARCH 1.3 (<http://www.cbrc.jp/research/db/TFSEARCH.html>) [@pone.0055473-Xu1] showed that the T-to-G base change of rs6682925 might affect a predicted GATA-X transcription factor binding, which may be involved in tumor differentiation and other carcinogenesis-related pathways [@pone.0055473-Bossard1], [@pone.0055473-Chou1]. Xu et al. found that the C allele (G allele in antisense strand) of rs6682925 may increase the promoter activity of *IL-23R* by luciferase assay, which was consistent with the web-based prediction [@pone.0055473-Xu1].

There are a few biases that may lead to spurious findings. Firstly, cases and controls were not matched on age and gender, but we used further statistical adjustment to minimize potential biases. Secondly, some risk predictors of AML, such as exposure to carcinogens and development of myelodysplasia, were not included in this analysis. Therefore, large population-based prospective studies with ethnically diverse populations are warranted to further elucidate the impact of *IL-23R* SNPs on AML susceptibility.

Materials and Methods {#s4}
=====================

Ethics Statement {#s4a}
----------------

The study is in compliance with the Helsinki declaration, and was approved by the institutional review board of Nanjing Medical University. The informed written consent was obtained from all subjects.

Study Subjects {#s4b}
--------------

All of the cases and controls were unrelated ethnic Han Chinese. The 545 newly diagnosed AML patients were consecutively recruited between December 2007 and August 2011 from Wuxi people's Hospital Affiliated to Nanjing Medical University. There were no restrictions in terms of age, stage of disease, or histology preventing people from participating in the study. The 1,146 controls were randomly selected from those participating in the community screening of non-communicable disease conducted in Jiangsu Province during the same period as the cases were recruited and had no self-reported cancer history. At the time of recruitment, informed consent was obtained from each subject, and each subject provided 5 ml of venous blood.

Laboratory Assays {#s4c}
-----------------

Genomic DNA was extracted from a leukocyte pellet by traditional proteinase K digestion followed by phenol-chloroform extraction and ethanol precipitation. SNPs rs6682925 T\>C and rs1884444 T\>G were genotyped by using the TaqMan allelic discrimination assay on an ABI 7900 system (Applied Biosystems, Foster city, CA). The primers and probes for rs6682925 and rs1884444 were described previously [@pone.0055473-Chu1].Genotyping was performed without knowing the subjects' case or control status. Two blank (water) wells in each 384-well plate were used for quality control and more than 10% samples were randomly selected to repeat, yielding a 100% concordant.

Statistical Analysis {#s4d}
--------------------

The χ^2^ tests were used to evaluate differences in the distributions of genotypes of the two variants between the cases and controls. Hardy-Weinberg equilibrium was tested by a goodness-of-fit χ^2^ tests to compare the observed genotype frequencies to the expected ones among the control subjects. The associations between *IL-23R* SNPs and AML risks were estimated by computing the odds ratio (ORs) and their 95% confidence intervals (CIs) from both univariate and multivariate logistic regression analysis. Homogeneity test among different strata according to selected variables was assessed with the χ^2^-based Q tests. All the statistical analyses were performed with SAS 9.1.3 software (SAS Institute, Cary, NC). *P*\<0.05 was the criterion of statistical significance, and all statistical tests were two sided.
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